Testing of hemoglobin A 1C (HbA 1C ) levels has become widespread in the management of patients with diabetes mellitus. Since the 1980s, it has proven to be an invaluable tool correlating with a patient's average blood glucose levels as well as with their disease morbidity. Clinicians often base treatment decisions and make adjustments depending on a patient's HbA 1C 
Diabetes mellitus afflicts more than 18 million people in the United States at an annual cost of $92 billion in direct medical expenses and approximately $40 billion in indirect expenses. 1 In patients with diabetes mellitus and hereditary spherocytosis (or any condition that results in a shortened erythrocyte life span), difficulties can arise with interpretation of hemoglobin A 1C (HbA 1C ) results. Presented is a patient with hereditary spherocytosis who, partly because of a falsely reassuring HbA 1C , was not diagnosed with diabetes mellitus despite meeting diagnostic criteria for several years.
Case Presentation
Mrs. J, a 43-year-old woman, presented to the family medicine clinic for her annual wellness examination. She had no active complaints and was feeling fine. Her past medical history was significant for gestational diabetes, hyperlipidemia, fatty liver, hereditary spherocytosis, and borderline diabetes. She reported a 30 pack-year smoking history, and her medications included folic acid, a daily multivitamin, and fenofibrate. At the time of evaluation, her physical examination was unremarkable. Review of her laboratory data showed a fasting glucose of 187 mg/dL, a hemoglobin of 10.6 g/dL, a hematocrit of 0.273, a total bilirubin of 2.4 mg/dL, and a HbA 1C of 0.048. The remainder of the results from her laboratory examinations was not clinically significant. Further review of her medical record revealed that her low hemoglobin and hematocrit as well as her elevated bilirubin were stable and consistent with her diagnosis of hereditary spherocytosis. Of particular note, her fasting glucose was well over the diagnostic cutoff for diabetes mellitus (Table 1) . Further review of her chart showed that Mrs. J had multiple fasting glucose values in the diabetic range dating back to 4 years before her current evaluation but was never diagnosed with diabetes mellitus. Over the last 2 years, her fasting glucose had ranged from 170 to 192 mg/dL ( 
Discussion
Hemoglobin, the protein molecule that transports oxygen throughout the body, resides predominantly in the red blood cell. When the red blood cell dies, the hemoglobin protein is released, broken down, and eventually excreted as bilirubin. The lifespan of the hemoglobin molecule is inherently related to the lifespan of the erythrocyte in which it resides. Under normal circumstances, this is approximately 120 days. During these 120 days, the hemoglobin molecule will be exposed to ambient glucose present in the circulation. Glycosylation or linkage of this circulating glucose to the hemoglobin molecule happens to approximately 5% of the adult hemoglobin (HbA) molecules. The glycosylation of HbA increases linearly over the lifespan of the red cell. 2 In the mid to late 1950s, it was noted that glycosylated HbA could be separated into at least 3 minor components designated HbA 1a , HbA 1b , and HbA 1C , the last of which is the most abundant. 3 By measuring the amount of HbA 1C present in the circulation and taking advantage of the knowledge of the linear increase of the glycosylation process over time, it became possible to obtain an estimate of a patient's average glucose level over the approximate 120-day lifespan of the hemoglobin protein found in the red blood cells (Table 3) . By the early 1980s, HbA 1C testing was widely available, and in subsequent years has proven to be invaluable in the management of patients with diabetes.
As useful as HbA 1C testing has become in the management of patients with diabetes, it does have notable limitations. A number of factors may confound the interpretation of the test result. Any condition that shortens the red cell lifespan, such as hereditary spherocytosis, hemolysis, sickle cell anemia, thalassemias, acute blood loss, or chronic blood loss will shorten the time of exposure of the hemoglobin protein to circulating glucose and decrease the glycosylation process. The HbA 1C measured under these circumstances would be falsely low and inaccurate. 2 Conversely, any condition which lengthens the red cell lifespan or slows red cell turnover and prolongs the time of exposure of 7 However, because of the shorter lifespan of serum proteins, fructosamine analysis correlates only with the average blood glucose over the previous 2 to 3 weeks. 8 Thus, a fructosamine analysis would need to be performed monthly to acquire the same information obtained with quarterly HbA 1C levels. There are also other disadvantages to using the fructosamine assay. Fructosamine values can vary with such changes in the synthesis or clearance of serum proteins as occurs with acute illness or liver disease. In addition, elevated uric acid levels, elevated bilirubin levels, or the presence of heparin may alter the results 2 . 8 The assay should not be performed if the serum albumin level is Յ3.0 mg/dL, because there is ongoing debate on whether to correct the results for serum protein or albumin levels. Finally, unlike the HbA 1C test, the fructosamine analysis has not been as extensively used or studied and consequently has not been proven to correlate with diabetic complications. 8 Although certainly not a perfect test, when used and interpreted appropriately, the fructosamine assay can be an important instrument in clinical situations where the HbA 1C is unreliable.
In addition to HbA 1C and fructosamine assays, monitoring daily home and office blood glucose levels of patients with diabetes is another appropriate management strategy. The benefit of blood glucose monitoring is that it gives a point of care result and allows for more timely changes in therapy. The levels of a patient's blood glucose monitoring can be used alone or in conjunction with HbA 1C and fructosamine assays to optimize the control of a patient's diabetes. Blood glucose monitoring does require a motivated and compliant patient and additional supplies, which may be construed by some as a barrier.
Although Mrs. J's fasting glucose levels had clearly met diagnostic criteria for diabetes mellitus for quite some time, her HbA 1C levels were never elevated because of the decreased number and shortened lifespan of her erythrocytes (Tables 1  and 2 
Summary
Clear criteria exist for the diagnosis of diabetes mellitus (Table 1 ). In Mrs. J's case, a coexisting disorder, hereditary spherocytosis, interfered with the accuracy of a test used to manage and monitor her other disorder, diabetes. This case illustrates the inherent inaccuracy of the HbA 1C assay in the setting of hemolytic disorders such as hereditary spherocytosis or any condition that alters the life span of the red blood cell. Clinicians should remember the importance of established diagnostic criteria for the diagnosis of diabetes mellitus and the need for the use of alternative methods, such as a fructosamine assay or blood glucose monitoring, when appropriate, to achieve long-term therapeutic success.
